RESEARCH GRANT AWARDS
AWARDS LIST.
Totals by Year
2023 - $891,364
2022 - $1,199,966
2021 - $749,812
2020 - $630,000
2019 - $690,000
2018 - $750,000
2017 - $747,772
2016 - $720,000
2015 - $840,000
2014 - $810,000
2013 - $808,500
2012 - $720,000
2011 - $599,780
2010 - $438,000
2009 - $435,000
2008 - $619,993
2007 - $232,600
2006 - $384,551
Amounts flagged (*) below are 50% funded by Cancer League of Colorado and 50% matched by MDC/RICHMOND AMERICAN HOMES FOUNDATION.
Jay Hesselberth, PhD and Linda vanDyk, PhD
Immune Targeting therapies to disrupt virus-associated lymphomas
$60,000*
2023
Marisa R Moroney, MD
Assessing the HDAC2/MTA3 Complex as an Epigenetic Driver in Gynecologic Carcinosarcomas
$30,000
2023
Richard Blake Ross, MD
Enhancing Immune-Mediated Radiotherapy Efficacy in Murine models of Head and Neck Cancer through Peroxisome Proliferator-Activated Receptor Modulation
$30,000*
2023
Bethany Veo, PhD
Evaluating IDH1 facilitation of radiation resistance in MYC-amplified MB
$30,000
2023
Brad Haverkos, MD and Eduardo Davila, PhD
Leveraging Chemoimmunotherapy to improve treatments for newly diagnosed aggressive T-cell lymphomas
$60,000*
2023
Sujatha Venkataraman, PhD, Mark Eric Kohler, PhD and Rajeev Vibhakar, MD
Preclinical testing of gated CAR-T cells in overcoming tumor antigen escape for effective immunotherapy against DIPG
$60,000*
2023
Kaylyn Utley, M.B, B.Ch., BAO
Effect of p53 on CAR T cell efficacy against acute leukemia
$30,000
2023
Carlo Marchetti, PhD, Todd Pitts, PhD
To investigate the role of NLRP3 in Pancreatic Ductal Adenocarcinoma (PDAC)-associated chemotherapy tolerance
$60,000
2023
Masanori Hayashi, MD and Srinivas Ramachandran, PhD
Investigation of cell-free DNA to define EWG-FLI1 activity in Ewing Sarcoma
$60,000*
2023
Mayumi Fujita, MD, PhD and Dinoop Ravindran Menon, PhD
The role of H3k4me3 remodeling in melanoma BRAF/MEK inhibitor resistance
$60,000
2023
Quentin Vicens, PhD
Targeting the BMI1 oncogene mRNA using small molecules
$30,000
2023
Dong Wang, MS, PhD
Targeting CDK8 as a therapeutic approach for MYC driven medulloblastoma
$30,000
2023
Shi Biao Chia, PhD
Influenza virus infection in reawakening dormant metastatic breast tumor cells in the lung
$30,000
2023
Nathan A. Dahl, MD
Deconvoluting enhancer rewiring in giloma relapse following radiotherapy
$30,000*
2023
Peter Kabos, MD, Srinivas Ramachandran, PhD
Personalization of care for patients with advanced microsatellite stable colon cancer
$60,000
2023
Elena Shagisultanova, MD, PhD
Choosing the right target: comparing PIK3CA and AKT inhibition in HER2+PIK3CA-mutated breast cancer
$30,000
2023
John Tentler, PhD
Cancer Research Summer Fellowship Program
$30,000
2023
Katherine Lind, MD
A feasibility study of family interviews after early death in childhood cancer
$21,497
2023
Rui Zhao, PhD
Understanding and inhibiting the EYA3 and PP2A-B55a interaction in triple-negative breast cancer
$30,000
2023
Zhirui Wang, PhD, Rajeev Vibhakar, MD, PhD, Sujatha Venkataraman, PhD
Development of Novel Dual CD99/B7-H3 immunotoxins against DIPG, a fatal brain tumor in children
$60,000
2023
Rebecca Schweppe, PhD
The role of subcellular localization of FAK in thyroid cancer
$30,000
2023
Kristine Corkum, MD
Validation and Implementation of a pediatric Oncofertility Risk Calculator for Children Diagnosed with an Extracranial Solid Tumor
$29,867
2023
John Tentler, PhD
Cancer Research Summer Fellowship Program
$30,000
2022
Michelle Williams, PhD
Targeting Heme Metabolism to Enhance Sensitivity to Immunotherapy in Metastatic Triple-Negative Breast Cancer
$30,000
2022
Jung-Jae Lee, PhD
Body heat activated storable, near-infrared, self-illuminating nanoprobes for in vivo optical imaging of cancer
$ 30,000
2022
Mayumi Fujita, MD, PhD
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
$59,969
2022
Matthew Witkowski, PhD
Targeting RNA-binding protein, NUDT21, enhances CD19 abundance on human B-cell acute lymphoblastic leukemia cells
$30,000
2022
Joshua Black, PhD and Heide Ford, PhD
Assessing the Prevalence of DNA Rereplication During Epithelial to Mesenchymal Transition in Breast Cancer
$60,000
2022
Martin Barrio, MD, MS
Identifying clinical and genetic features associated with thyroid cancer risk of recurrence
$30,000
2022
Jessica Floyd, MD
Modulation of the immune suppressed tumor microenvironment in high grade serous ovarian cancer through interventions in the tryptophan catabolism pathway
$30,000
2022
Takamitsua Kato, PhD
Investigation of mechanisms and feasibility for chemo/radio-sensitization for cancer therapy by SQAP
$30,000
2022
Nicholas Foreman, MD
Integration of single-nuclei RNA-sequencing and spatial transcriptomics to study the transformation of highly aggressive malignant peripheral nerve sheath tumors
$ 30,000
2022
Tejas Patil, MD and Lynn Heasley, PhD
Programmed death receptor (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC
$60,000
2022
Sujatha Venkataraman, PhD and Eric Kohler, MD, PhD and Masanori Hayashi, MD
Pre-clinical evaluation of "SMART CAR"-T cell therapy against primary and metastatic Ewing sarcoma
$60,000
2022
Khosbayar Lkhagvadorj, PhD
An ex-vivo organoid model to identify markers of lung adenocarcinoma premalignancy
$30,000
2022
Molishree Joshi, PhD, Scott Cramer, PhD, and James Costello, PhD
Vitamin D synthetic lethal network across benign and metastatic cell lines
$60,000
2022
Paul Jedlicka, MD, PhD
Understanding new mechanisms cooperating with the PAX3/FOX01 driver oncofusion in rhabdomyosarcoma
$ 30,000
2022
Douglas H. Thamm, VMD, DACVIM
Antitumor and Antimetastatic Effects of MYC Depletion with Omacetaxine in Osteosarcoma
$29,997
2022
Robert Meguid, MD, PhD, and Christina Stewart, MD
Pilot Development of an Enriched Cancer Database using Machine Learning Techniques
$30,000
2022
Eric T. Clambey, PhD and Raphael A. Nemenoff, PhD
Role of Cancer-cell specific MHC II in regulating response to immune checkpoint inhibitors in lung cancer
$60,000
2022
Yiqun Shellman, PhD and Richard Tobin, PhD
Investigating the role of host Sash 1 expression in antitumor Immunity
$60,000
2022
Nathan Dahl, MD and Rajeev Vibhakar, MD, PhD, MPH
CDK9 as a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
$60,000
2022
Zdenek Andrysik, PhD
Pre-clinical test of colorectal cancer therapy based on combinatorial activation of p53 and Integrated Stress Response
$ 30,000
2022
Todd Pits, PhD, and Julie Lang, PhD
Anti-TIGIT antibody in combination with bevacizumab/DC101 and pembrolizumab in microsatellite stable colorectal cancer
$60,000
2022
Mohamed Ghoneim, PhD
Mechanisms of PBAF Remodeling Complex and Effect of Cancer Mutations
$30,000
2022
Keara Boss, DVM, PhD and Steven Dow, DVM, PhD
Establishing a novel orthotopic sinonasal carcinoma model in immunocompetent rats for translational radiation and immunotherapy research
$60,000
2022
Reema Wahdan, PhD and Daniel LaBarbera, PhD
Targeting Thyroid Hormone-Mediated Cancer Stem Cell Expansion and Treatment Resistance in ER+ Breast Cancer cells
$60,000
2022
Joselyn Cruz Cruz, PhD
Reversing Immunosuppression in Rhabdomyosarcoma
$ 30,000
2022
Jeffrey Moore, PhD
Mechanism of Chemotherapeutic Resistance by TUBB3 Tubulin
$30,000
2022
Shi-Long Lu, MD, PhD and Daniel Frank, PhD
Functional assessment of human microbiome in head and neck cancer mouse models
$60,000
2022
Takeshi Yamauchi, PhD
Non-UV risk factors of melanoma
$30,000
2021
Siddhartha Mitra, PhD
Development of Chimeric Antigen Receptor Expressing macrophages and microglia to target pediatric glioblastoma
$30,000
2021
Rajeev Vibhakar, MD, PhD, MPH
Role of BMI1 in SMARB1 deleted ATRTs
$30,000
2021
Masanori Hayashi, MD
Preclinical Investigation of BCOR rearranged solid tumors
$30,000
2021
Matthew J. Sikora, PhD
Targeting an unexplored DNA repair deficiency and radiosensitivity in lobular breast cancer
$30,000
2021
Carol Sartorius, PhD
Lipodependence of endocrine resistant breast cancer as a therapeutic target
$30,000
2021
John Tentler, PhD
Cancer Research Summer Fellowship Program
$30,000
2021
Satyanarayan Rao, PhD
Using transcription factors to map tumor state and microenvironment
$30,000
2021
Jennifer Matsuda, PhD and James Scott-Browne, PhD
Genetic manipulation of human T cell transcriptional programs to improve cancer immunotherapy
$60,000
2021
Leonora Slatnick, MD
Biomarker Development for Sepsis in Pediatric Oncology Patients
$30,000
2021
Carlo Marchetti, PhD and Mayumi Fujita, MD, PhD
Identifying the role of NLRP3 in immunotherapy resistant melanomas
$60,000
2021
Andrew Getahun, PhD and John Cambier, PhD
Identification of novel inhibitory checkpoint receptors
$60,000
2021
Adam Green, MD and Natalie Serkova, PhD and Mark Borden, PhD
MRI-Guided Focused Ultrasound to Improve Treatment of DIPG
$60,000
2021
Sujatha Venkataraman, PhD
Novel CAR T cell therapies to target metastatic Ewing Sarcoma
$30,000
2021
Paul Jedlicka, MD, PhD
Understanding the metastasis-promoting cistrome in Ewing Sarcoma
$30,000
2021
Santos Franco, PhD, Siddhartha Mitra, PhD and Adam Green, MD
Development of In utero driven Mouse Models of Diffused Midline Gliomas to study the tumor immune interactions in Pediatric Midline Gliomas
$60,000
2021
Elizabeth Kessler, MD
Validation of a patient-reported tool to screen for geriatric impairments predictive of potential frailty in cancer patients
$29,812
2021
Dr. Michael Veneris and C. Wyatt Shields, PhD
Assessment of Cell Types for Delivering MerTK Inhibitors to Sarcomas
$60,000
2021
Nathan Dahl, MD
Unlocking the combination: Potentiation of radiation-induced antitumor effect using clinically-relevant BH3 mimetics to effectively target DIPG
$30,000
2021
Paula Jedlicka, MD, PhD
Understanding and targeting highly metastatic EWS/FLi1-low cells in Ewing Sarcoma
$ 30,000
2020
Ryan Marker, PhD
Feasibility and effectiveness of an Innovative exercise program to reduce fatigue in rural cancer survivors
$ 30,000
2020
Zdenek Andrysik PhD
Exploring strong synergism of targeted p53 activation and translation inhibition in colorectal cancer.
$ 30,000
2020
Senthilnath Lakshmana Chetty, PhD
Combining radiation and Immunotherapy to target diffuse midline gliomas with the H3K27M mutation
$ 30,000
2020
Breelyn Wilky, MD & Eduardo Davila, PhD
Toxicity and Biodistribution of CD*:MyD88 Engineered Autologous T Cells In Mouse Models of Melanoma and Fibrosarcoma
$ 60,000
2020
Zachary Graff, MD
Development of Bispecific CAR T-cells for the Prevention of Lineage Switch in KMT2A-rearranged Leukemia
$ 30,000
2020